The sale of Santalis is another option. Quintus probably can't afford the forthcoming phase-3 HPV trial without a cash injection, so a Santalis sale might be smart.
I would think that the cash from a Santalis sale would safely get Quintus through to their large harvest years without the need for any cap raises or plantation sales.
Although I agree that it is likely some or all of the put options will be exercised. If they're not exercised, I'm not sure any of the above measures will be necessary. And the put options do give QIN plantations at a roughly 50% discount to their book value. I agree that the current book values are doubtful, but are they over-valued by 50%?
It will be interesting to see if Frank Wilson exercises his put options when the time comes.
- Forums
- ASX - By Stock
- QIN
- Where to from here
Where to from here, page-2
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add QIN (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online